Ginkgo Bioworks Holdings, Inc.
DNA
$9.34
-$0.56-5.66%
NYSE
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -21.71% | 2.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -21.71% | 2.66% | |||
| Cost of Revenue | -13.63% | 23.03% | |||
| Gross Profit | -25.15% | -4.11% | |||
| SG&A Expenses | 3.87% | -11.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.03% | -15.56% | |||
| Operating Income | -42.68% | 26.08% | |||
| Income Before Tax | -33.29% | 33.33% | |||
| Income Tax Expenses | 100.35% | -421.59% | |||
| Earnings from Continuing Operations | -33.92% | 33.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -33.92% | 33.70% | |||
| EBIT | -42.68% | 26.08% | |||
| EBITDA | -91.22% | 32.57% | |||
| EPS Basic | -32.05% | 34.45% | |||
| Normalized Basic EPS | -43.87% | 31.58% | |||
| EPS Diluted | -31.95% | 34.52% | |||
| Normalized Diluted EPS | -43.87% | 31.58% | |||
| Average Basic Shares Outstanding | 1.41% | 1.14% | |||
| Average Diluted Shares Outstanding | 1.41% | 1.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||